Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wei Shen Tan

Showing results (1-10 of 117) with videos related to

Pageof 12
Sort By:
BJU International|July 4, 2026
A call for regimen agnostic circulating tumour DNA-guided adjuvant selection in muscle-invasive bladder cancerFady Ghali, Wei Shen Tan
Translational Andrology and Urology|April 13, 2018
Urinary biomarker for the detection of recurrence following non-muscle invasive bladder cancer: are we there yet?Wei Shen Tan, Wei Phin Tan
The Journal of Urology|April 14, 2020
Editorial CommentWei Shen Tan, John D Kelly
Nature Reviews. Urology|March 27, 2021
Is delay to radical cystectomy following BCG failure oncologically safe?Wei Shen Tan, John D Kelly
European Urology|October 22, 2022
Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003Wei Shen Tan, John D Kelly,
Nature Reviews. Urology|September 27, 2018
Intravesical device-assisted therapies for non-muscle-invasive bladder cancerWei Shen Tan, John D Kelly
Translational Andrology and Urology|January 29, 2019
Is experience with extracorporeal urinary diversion following robotic assisted radical cystectomy necessary before transitioning to intracorporeal urinary diversion?Wei Shen Tan, John D Kelly
European Urology|November 28, 2017
Factors Affecting the Cost of Radical Cystectomy in the USA: Some Centres Are More Equal than OthersPramit Khetrapal, Wei Shen Tan, John D Kelly
The Medical Journal of Australia|October 2, 2022
Robotic surgery: getting the evidence rightWei Shen Tan, Anthony Ta, John D Kelly
European Urology|December 1, 2022
Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003Wei Shen Tan, Connor Mustard, John D Kelly, et al.
Pageof 12

Showing results (1-10 of 117) with videos related to

Sort By:
Pageof 12
BJU International|July 4, 2026
A call for regimen agnostic circulating tumour DNA-guided adjuvant selection in muscle-invasive bladder cancerFady Ghali, Wei Shen Tan
Translational Andrology and Urology|April 13, 2018
Urinary biomarker for the detection of recurrence following non-muscle invasive bladder cancer: are we there yet?Wei Shen Tan, Wei Phin Tan
The Journal of Urology|April 14, 2020
Editorial CommentWei Shen Tan, John D Kelly
Nature Reviews. Urology|March 27, 2021
Is delay to radical cystectomy following BCG failure oncologically safe?Wei Shen Tan, John D Kelly
European Urology|October 22, 2022
Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003Wei Shen Tan, John D Kelly,
Nature Reviews. Urology|September 27, 2018
Intravesical device-assisted therapies for non-muscle-invasive bladder cancerWei Shen Tan, John D Kelly
Translational Andrology and Urology|January 29, 2019
Is experience with extracorporeal urinary diversion following robotic assisted radical cystectomy necessary before transitioning to intracorporeal urinary diversion?Wei Shen Tan, John D Kelly
European Urology|November 28, 2017
Factors Affecting the Cost of Radical Cystectomy in the USA: Some Centres Are More Equal than OthersPramit Khetrapal, Wei Shen Tan, John D Kelly
The Medical Journal of Australia|October 2, 2022
Robotic surgery: getting the evidence rightWei Shen Tan, Anthony Ta, John D Kelly
European Urology|December 1, 2022
Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003Wei Shen Tan, Connor Mustard, John D Kelly, et al.
Pageof 12